Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High versus moderate emetic risk prophylaxis in modified FOLFIRINOX for pancreatic adenocarcinoma
TCTR20250130003Phase 3Recruiting
- Sponsor
- Siriraj Oncology Foundation
- Start
- Feb 2025
- Countries
- 1
01
Overview
Phase 3, randomised trial in pancreatic adenocarcinoma (PDAC) and chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Siriraj Oncology Foundation. Started Feb 2025; status: recruiting.
02
Conditions
pancreatic adenocarcinoma (PDAC)chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on TCTR20250130003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20250130003.